On the stock market since 2021, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 81% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 26% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 37% a year on average.
Sales run at $100.6M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 34 buys and 19 sells. Management buying with its own money is usually read as a good sign.
A loss of $81.8M against $100.6M in annual sales.
On our five-subject report card, CFVIU sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CFVIU is a high-risk stock — not yet profitable, and its future rides on its product catching on.